Xenotransplantation, the use of animal organs in human recipients offers a possible solution to organ shortages but faces notable scientific, ethical, and regulatory hurdles. Major issues include immune rejection, zoonotic infection risks, long-term monitoring, participant vulnerability, animal welfare concerns, and equitable access. Effective oversight, transparent consent, multidisciplinary collaboration, and ongoing research are essential for success of clinical trials. This article reviews major ethical and regulatory considerations and outlines recommended practices for sponsors and Institutional Review Boards (IRBs) engaged in xenotransplantation clinical trials.
The global shortage of human donor organs remains one of the most persistent and life-limiting challenges in modern medicine. Thousands of patients die each year while waiting for a suitable organ, highlighting the need for innovative solutions. In the United States, more than 103,000 people are on the transplant waiting list, and 13 die daily waiting for organs. About 86% need a kidney, 9% need a liver, and 3% need a heart. Xenotransplantation, the transplantation of organs, tissues, or cells from non-human animals into humans has emerged as a promising frontier, potentially offering a virtually limitless supply of donor organs. With recent advances in genetic engineering and immunology, the transplantation of genetically modified pig organs into human recipients is transitioning from experimental feasibility to clinical reality. However, this unprecedented progress brings equally significant regulatory, ethical, and public health challenges. A deeper look at the key ethical and regulatory issues will provide recommended practices for sponsors and Institutional Review Boards (IRBs) involved in xenotransplantation clinical trials.
Scientific Advances and Remaining Hurdles
The scientific landscape of xenotransplantation has evolved rapidly, driven by the application of gene-editing technologies such as CRISPR to create genetically modified pigs whose organs are less likely to be rejected by the human immune system.
Notable milestones include the successful transplantation of pig hearts and kidneys into human recipients under expanded access protocols, which have demonstrated that animal organs can function in human bodies for limited durations. These first-in-human cases are invaluable for understanding immune responses and refining surgical techniques.
Despite these advances, several formidable hurdles remain. Immune rejection, both immediate and delayed, continues to pose a significant challenge, necessitating the use of powerful immunosuppressive therapies with their own risks. The possibility of zoonotic infections, where diseases are transmitted from animals to humans, is a persistent concern, especially with the potential emergence of novel pathogens. Vigilant screening, lifetime monitoring of recipients, and surveillance of close contacts are essential strategies to mitigate the risk of zoonosis. However, the possibility of unforeseen infectious outbreaks remains a public health consideration.
The long-term durability and functionality of xenografts are not yet fully understood, and standardising protocols for the production and use of genetically engineered animal organs remains a work in progress. Technical challenges in organ procurement, preservation, and transplantation further complicate the path to routine clinical use.
